I am amazed at the changing landscape over the past seven years when it comes to melanoma treatment options. I am happy to report I am still NED after going off the Braf/MEK combo. I am working to help fund future research project and skin cancer awareness. Next month I will start working on a skin cancer program targeted to the construction industry.
Cool facts:
Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
Nivolumab plus ipilimumab, in contrast with ipilimumab alone, may improve overall survival of patients with previously untreated, advanced melanoma, according to a study published in The Lancet Oncology.
Researchers have found that removing a particular enzyme and protein from the immune system significantly reduces the spread of breast cancer and melanoma.
Candidates for this procedure must have good liver function and not many tumors. If ocular melanoma is localized to the eye, prognosis is good, but 50 percent of ocular melanoma cancers spread.
Be extra careful if you’ve got body art…
Researchers have established its ability to provide potent anti-inflammatory properties, which inhibit cyclooxygenase enzymes in the same way as NSAID ibuprofen.
I am excited to be living at time when research and discovery are on the forefront for melanoma cancer. Remember to research, read and ask questions. An educated patient lives longer
Leave a Reply